PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

EXPRESS MAIL LABEL NO. EV 22J20162705

DATE OF DEPOSIT _____

U	inder the Paperwork Reduction Act of 1995.	no perso	ns are required to respond to a collection	n of infor	mation unless it displays a valid OMB control number	
TRANSMITTAL FORM (to be used for all correspondence after initial to		Application Number		09/027,205		
			Filing Date	February 20, 1998		
			First Named Inventor	Carl June let al.		
		filing)	Art Unit	1644		
		Examiner Name		J. Roark		
Tota	al Number of Pages in This Submission	4	Attorney Docket Number	3611	9.126US1	
ENCLOSURES (Check all that apply)						
		1,412, 48	(00000000000000000000000000000000000000		After Allowance communication	
	Fee Transmittal Form		Drawing(s)		to Technology Center (TC)	
	Fee Attached		Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
	Amendment/Reply		Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
	After Final		Petition to Convert to a Provisional Application		Proprietary Information	
	Affidavits/declaration(s)	1.00	Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer		Status Letter	
	Extension of Time Request				Other Enclosure(s) (please Identify below):	
	Express Abandonment Request		Request for Refund	equest for Refund		
	Information Disclosure Statement		CD, Number of CD(s)			
	Certified Copy of Priority Document(s)	- Supplemental Response to Update Interview Summary				
	Response to Missing Parts/ Incomplete Application Pursuant to 37 C.F.R. Sec. 1.133 (3 Pages) Return Postcard				1.133 (3 Pages)	
		- Return Postcard				
	Response to Missing Parts under 37 CFR 1.52 or 1.53					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm						
or Individual name Collegn/Superko, Reg., No. 39,850						
Signature William Julian Julia						
Date May 14, 2004						

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

05-17-04



1644 TPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Serial No.:

Carl June et al.

09/027,205

Filing Date:

February 20, 1998

Docket No.:

36119-126US1

Title:

Methods for Modulating Expression of

an HIV-1 Fusion Cofactor

Art Unit:

1644

Examiner:

J. Roark

Conf. No.:

2825

Cust. No.:

23483

CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EV 225201627

Express Mail No.

Date of Deposit

Sharon R. Matthews

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL RESPONSE TO UPDATE EXAMINER'S INTERVIEW SUMMARY PURSUANT TO 37 C.F.R. § 1.133

DearSir:

Further to the Amendment and Response under 37 C. F.R. § 1.111, filed March 5, 2004, Applicants hereby supplement said Response by additionally clarifying the telephonic Examiner's Interview conducted on March 4, 2004 in the above-referenced application. An Examiner's Interview Summary dated March 26, 2004 was subsequently received by Applicants on March 29, 2004.

INTERVIEW SUMMARY

On March 4, 2004, a telephonic Examiner's interview was held with Colleen Superko and Joseph Koipally participating on behalf of the Applicants, and Examiners Jessica Roark and Phillip Gambel participating from the United States Patent and Trademark Office.

Prior to the Examiner's Interview, Applicants' representatives forwarded by facsimile both Examiners a copy of a Declaration under 37 C.F.R. § 1.132, executed by Dr. Carl June on June 4, 2003 and filed with the Response of July 17, 2003 and a copy of a draft Declaration to address the alleged deficiencies of the June 4, 2003 Declaration raised in the Office Action of November 5, 2003.

Applicants' representatives initially provided an overview of the background of the claimed invention and its importance to the field of immunology.

Applicants' representatives proceeded to discuss the outstanding 35 U.S.C. § 102 rejections and inquired whether the draft Declaration would overcome those rejections. The Examiners indicated that the draft Declaration would likely not overcome the outstanding rejections, contrary to what had been previously stated in the Office Action (*see*, Office Action of January 17, 2003, page 6, fifth paragraph; and Office Action of November 5, 2003, page 8, fifth paragraph).

Applicants' representatives and the Examiners then discussed proposed claim language to distinguish over the cited documents. Specifically, the Examiners suggested that inclusion of a measuring step for assaying expression levels of CCR5/HIV fusion cofactors would appear to distinguish the claims over the cited documents. However, Examiner Roark indicated that she would need to conduct an updated search of the proposed amended claims to determine if the claims were patentable over the cited documents.

PATENT Appl. No. 09/027,205 Suppl. Amdt. dated May 14, 2004

Applicants indicated that they would consider the Examiners' suggestions in preparing the Amendment and Response to the outstanding Office Action. Notably, the March 5, 2004 Amendment included this proposed claim language in the independent method claims 95-98.

CONCLUSION

No fees are believed to be due in connection with this Supplemental Response. However, if any fees are due, please debit our Deposit Account No. 08-0219 for the requisite fee.

The Examiner is invited to telephone the undersigned at the telephone number given below in order to expedite the prosecution of the instant application.

Respectfully submitted,

Date: May 14, 2004

Collen Superko Colleen Superko Reg. No. 39,850

HALE AND DORR LLP 60 State Street Boston, MA 02109

Tel.: (617) 526-6564

Fax: (617) 526-5000